心臟起搏器市場：依產品（植入式心律調節器[雙腔起搏器、CRT心律調節器]、體外心律調節器、起搏導線）、適應症（心律不整、心臟衰竭）和最終用戶（醫院/診所、門診中心） - 至2036年的預測

2025年全球心臟節律器市場規模約39.9億美元。預計該市場將從2026年的41.1億美元成長到2036年的約56.3億美元，2026年至2036年的年複合成長率為3.2%。

心臟節律器市場涵蓋多種目的是向心肌傳遞電脈衝並調節心臟節律的醫療設備。這些裝置對於患有心搏過緩、心律不整和其他心律不整的患者非常重要，其中包括植入式起搏器（例如雙腔起搏器和心臟再同步治療（CRT）起搏器）以及體外起搏器和起搏導線。市場成長的主要驅動因素是心血管疾病（包括心律不整和充血性心臟衰竭（CHF））盛行率的上升、人口老化以及起搏器技術的不斷進步。

無導線起搏器和具有遠端監測功能的設備的開發顯著改善了患者的治療效果，並擴大了市場潛力。本報告對全球五大主要地區的心臟節律器設備市場進行了全面分析，重點關注當前市場趨勢、市場規模、近期發展以及到2036年的預測。基於廣泛的二級和一級研究以及詳細的市場情境分析，本報告對關鍵產業驅動因素、限制因素、機會和挑戰進行了影響分析。

主要市場趨勢

無導線起搏器和微創技術的發展：向無導線起搏器的轉變是心臟起搏器市場最具創新性的趨勢之一。與傳統的經靜脈系統不同，無導線裝置是直接植入右心室的獨立單元，消除了傳統起搏器長期併發症的兩大主要原因：導線和手術囊袋。這種設計顯著降低了導線斷裂、靜脈阻塞、囊袋感染和裝置侵蝕等風險。長期資料表明，無導線起搏器具有卓越的安全性和性能，因此在臨床上的應用日益廣泛。Abbott Laboratories的Aveir VR無導線心律調節器具有可回收性和長壽命電池，克服了傳統心律調節器的限制。Medtronic公司的Micra AV透過基於加速度計的感測技術實現房室同步，擴大了適用人群，不再局限於單腔起搏患者。這些創新對老年患者、靜脈通路受限的患者、感染風險高的患者尤其重要。

整合遠端監測和無線連接：將遠端患者監測（RPM）和無線連接功能整合到起搏器系統中，重塑植入後護理模式。現代心律調節器可以持續向臨床醫生傳輸設備診斷資訊、心律不整負荷資料和電池狀態，實現主動干預並減少常規的面對面隨訪。越來越多的臨床證據表明，遠端監測能夠改善患者預後並降低住院率。Boston Scientific的LATITUDE NXT 遠端病患管理系統和Biotronik的家庭監測服務等平台，可針對心律不整事件、導線效能問題和設備完整性問題提供自動警報。與智慧型手機應用程式和雲端生態系統的整合，能夠促進患者參與，並支持以價值為導向的護理模式，透過持續監測減少再住院和長期護理成本。

MRI相容型和雙功能治療設備的進展：MRI相容型心律調節器的技術創新拓展其臨床應用，並增加患者接受診斷影像的機會。結合心律調節器和除顫器功能的雙功能治療設備能夠滿足複雜心律不整的治療需求。這些進展改善了患者的治療效果，並支持在不同臨床族群中廣泛應用相關技術。

市場區隔

依產品劃分

依產品劃分，預計2026年，植入式心律調節器將佔據最大的市場佔有率。這一主導地位歸功於這些設備在治療慢性心律不整方面的長期有效性和可靠性。雙腔起搏器是目前最先進的植入式起搏器類別，它透過協調心房和心室收縮來實現生理性起搏，提高血流動力學效率並改善患者預後。心臟再同步治療（CRT）起搏器適用於伴有室性心律不整的心臟衰竭患者，它能向雙側心室提供同步電刺激，恢復協調的收縮模式。這些裝置已證實能顯著改善心臟衰竭患者的運動耐受性、生活品質和存活率。體外心律調節器雖然市場佔有率較小，但意義重大，主要用於急診護理，例如心臟急症的臨時起搏、術後管理以及永久性裝置植入前的過渡治療。起搏導線是連接起搏器產生器和心肌組織的關鍵零件，目前正持續進行創新，以提高導線的耐用性、感知能力和生物相容性。無導線起搏器雖然目前市場佔有率較小，但卻是成長最快的細分市場。無導線裝置無需傳統導線和手術囊袋，顯著降低了導線斷裂、靜脈阻塞、囊袋感染和裝置侵蝕等長期併發症的發生率。Abbott Laboratories的Aveir VR和Medtronic公司的Micra AV是先進的無導線起搏平台，具備導線回收和房室同步功能，擴大了適用患者群體，並促進了其在各種臨床環境中的應用。

依適應症劃分

依適應症劃分，預計到2026年，心律不整將佔據最大的市場佔有率。心搏過緩和心房顫動等心律不整是起搏器植入最常見的適應症。心搏過緩的特徵是心率異常緩慢，在老年人中更為常見。它可能由竇房結功能障礙或房室傳導阻滯引起。心房顫動是最常見的心律不整，影響全球數百萬人，通常需要採用心率控制型心律調節器策略。這些疾病的日益普遍，以及患者和醫療保健提供者對起搏器治療益處的認識不斷提高，推動該領域的成長。充血性心臟衰竭（CHF）是第二大適應症，CRT 心律調節器專門用於治療心臟衰竭患者的室性心律不整。由於老化、高血壓、糖尿病和冠狀動脈疾病導致的心臟衰竭盛行率不斷上升，創造了巨大的市場機會。 CRT 心律調節器已展現出顯著的臨床效益，包括改善左心室射血分數、降低住院率和提高存活率，支持其在心臟衰竭管理方案中的應用。

依最終用戶劃分

依最終用戶劃分，醫院和診所將在整個預測期內佔據主要佔有率。這些機構擁有先進的電生理實驗室，配備了進行複雜起搏器植入手術所需的精密成像和監測設備。醫院擁有專業的電生理團隊，他們在設備選擇、植入技術和術後管理方面接受過廣泛的培訓。門診中心是一個成長領域，尤其是在常規設備植入和後續治療方面。這些機構為住院手術提供了一種經濟高效的替代方案，提高了患者就醫便利性並降低了醫療成本。由於手術效率的提高、感染風險的降低以及患者便利性的提升，向門診模式的轉變加速。這兩種類型的機構都在日益整合遠端監測平台，實現持續的設備監測和主動的臨床干預。

區域分析

這份詳細的產業區域分析報告深入探討了五大主要區域（北美、歐洲、亞太、拉丁美洲以及中東和非洲）及其主要國家的市場狀況，並提供了定性和定量分析。預計在整個預測期內，北美將佔據全球心臟起搏器設備市場最大的佔有率。該地區的領先地位得益於心血管疾病（包括心律不整和心臟衰竭）的高發病率，而隨著人口老化，這些疾病的發生率仍在持續上升。北美地區擁有完善的醫療保健基礎設施、先進的電生理中心以及強大的心臟器械植入手術臨床經驗。有利的償付機制和廣泛的保險覆蓋提高了患者獲得植入式心臟器械的機會，推動了技術先進的起搏器系統的普及。 MRI相容型心律調節器、無導線心律調節技術和遠端監測平台等創新技術的早期應用，進一步增強了該地區的需求。Medtronic、Abbott Laboratories和Boston Scientific等領先製造商的強大實力，為持續的產品創新、臨床研究和醫生培訓提供了支持。

預計亞太地區將在預測期內成為全球心臟節律器市場成長最快的地區。這一成長主要受心血管疾病負擔加重、人口老化迅速加劇以及診斷和治療率提高的推動。醫療保健支出增加、醫院基礎設施擴建以及政府為提高先進心臟護理服務可及性而採取的舉措，都促進了市場成長。人們對微創心臟手術的認識不斷提高，以及植入式心臟器械的普及，推動該地區的需求成長。中國和印度等主要經濟體憑藉其龐大的患者群體、不斷擴張的私人醫療保健行業以及對醫療技術日益成長的投資，成為關鍵的成長引擎。區域製造商的日益壯大以及心臟器械價格的不斷下降也進一步推動了市場滲透。

歐洲市場正經歷穩定成長，這得益於其先進的醫療保健體系、強大的臨床研究基礎以及創新心臟技術的高普及率。拉丁美洲以及中東和非洲是新興市場，這些地區對醫療保健基礎設施的投資不斷增加，並且越來越意識到心臟器材在心血管疾病管理中的重要性。

目錄

第1章 引言

第2章 研究方法

第3章 執行摘要

第4章 市場洞察

• 市場動態
  • 驅動因素
    • 心血管疾病和心律不整盛行率上升
    • 易患心臟病的老年人口增加
    • 微型化與MRI相容型心律調節器的技術進步
    • 微創手術的日益普及
  • 限制因素
    • 植入式心臟裝置的高成本
    • 產品召回與器械相關併發症
    • 嚴格的監理審批流程
  • 機會
    • 新興市場醫療保健服務覆蓋範圍擴大
    • 無導線和無線心律調節器技術的發展
    • 對整合式遠距患者監護的需求不斷成長
  • 趨勢
    • 向無導線起搏器過渡
    • 人工智慧（AI）與先進診斷技術的融合
    • 居家心臟監測生態系的發展
• 波特五力分析

第5章 心臟節律器設備市場（依產品）

• 植入式心律調節器
  • 雙腔心律調節器
  • 單腔起搏器
  • 心臟再同步治療（CRT）心律調節器
• 體外心律調節器
• 起搏導線
  • 主動固定導線
  • 被動固定導線

第6章 心臟節律器市場（依適應症劃分）

• 心律不整
• 充血性心臟衰竭（CHF）
• 其他適應症

第7章 心臟節律器市場（依最終用戶劃分）

• 醫院和診所
• 門診中心
• 其他最終用戶

第8章 心臟節律器市場（依地區劃分）

• 北美
  • 美國美國
  • 加拿大
• 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳洲
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 中東和非洲其他地區

第9章 競爭格局

• 市場佔有率分析
• 競爭成長策略
• 產品基準分析
• 供應商定位矩陣

第10章 公司簡介

• Medtronic plc
• Abbott Laboratories
• Boston Scientific Corporation
• BIOTRONIK SE &Co. KG
• LivaNova PLC
• MicroPort Scientific Corporation
• Lepu Medical Technology
• Shree Pacetronix Ltd.
• Oscor Inc.
• Cook Medical
• 其他

第11章 附錄

Cardiac Pacemaker Devices Market by Product (Implantable Pacemakers [Dual Chamber, CRT Pacemaker], External Pacemaker, Pacing Leads), Indication (Arrhythmia, Congestive Heart Failure), End User (Hospitals & Clinics, Ambulatory Care Centers), and Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) - Global Forecast to 2036

According to the research report titled, 'Cardiac Pacemaker Devices Market by Product (Implantable Pacemakers [Dual Chamber, CRT Pacemaker], External Pacemaker, Pacing Leads), Indication (Arrhythmia, Congestive Heart Failure), End User (Hospitals & Clinics, Ambulatory Care Centers), and Region - Global Forecast to 2036,' the global cardiac pacemaker devices market was valued at approximately USD 3.99 billion in 2025. This market is expected to reach approximately USD 5.63 billion by 2036 from USD 4.11 billion in 2026, growing at a CAGR of 3.2% from 2026 to 2036.

The cardiac pacemaker devices market encompasses a range of medical devices designed to regulate the heart's rhythm by delivering electrical impulses to the heart muscle. These devices are critical for patients suffering from bradycardia, arrhythmia, and other heart rhythm disorders, including implantable pacemakers such as dual-chamber and cardiac resynchronization therapy (CRT) pacemakers, as well as external pacemakers and pacing leads. The growth of this market is primarily driven by the rising prevalence of cardiovascular diseases, including arrhythmia and congestive heart failure (CHF), a growing geriatric population, and continuous technological advancements in pacemaker technology.

The development of leadless pacemakers and devices with remote monitoring capabilities has significantly improved patient outcomes and expanded the market potential. The report provides comprehensive analysis of the global cardiac pacemaker devices market across five major regions, emphasizing current market trends, market sizes, recent developments, and forecasts till 2036. Following extensive secondary and primary research and in-depth market scenario analysis, the report conducts impact analysis of key industry drivers, restraints, opportunities, and challenges.

Key Market Trends

Development of Leadless Pacemakers and Minimally Invasive Technologies: The shift toward leadless pacemakers represents one of the most transformative technological trends in the cardiac pacemaker market. Unlike traditional transvenous systems, leadless devices are self-contained units implanted directly into the right ventricle, eliminating leads and surgical pockets-the two major sources of long-term complications in conventional pacemakers. This design significantly reduces risks associated with lead fracture, venous obstruction, pocket infections, and device erosion. Clinical adoption is increasing as long-term data demonstrate favorable safety and performance outcomes. Abbott Laboratories' Aveir VR leadless pacemaker features retrievability and extended battery longevity, addressing earlier limitations. Medtronic's Micra AV enables atrioventricular synchrony using accelerometer-based sensing, expanding eligible patient populations beyond single-chamber pacing candidates. These innovations are particularly valuable for elderly patients, those with limited venous access, and individuals at high risk of infection.

Integration of Remote Monitoring and Wireless Connectivity: The incorporation of remote patient monitoring (RPM) and wireless connectivity into pacemaker systems is reshaping post-implantation care models. Modern pacemakers enable continuous transmission of device diagnostics, arrhythmia burden data, and battery status to clinicians, allowing proactive intervention and reducing routine in-person follow-ups. Growing clinical evidence links remote monitoring with improved patient outcomes and reduced hospitalization rates. Platforms such as Boston Scientific's LATITUDE NXT Remote Patient Management System and Biotronik's Home Monitoring Service offer automated alerts for arrhythmic events, lead performance issues, and device integrity concerns. Integration with smartphone applications and cloud-based ecosystems enhances patient engagement and supports value-based healthcare models where continuous monitoring reduces readmissions and long-term care costs.

Advancement in MRI-Compatible and Dual-Therapy Devices: Technological innovations enabling MRI compatibility in pacemakers are expanding clinical applications and patient access to diagnostic imaging. Dual-therapy devices combining pacing with defibrillation capabilities address complex arrhythmia management needs. These advancements improve patient outcomes and support broader procedural adoption across diverse clinical populations.

Market Segmentation

Based on Product

By product, the Implantable Pacemakers segment is expected to account for the largest share of the market in 2026. This dominance is attributed to the long-term efficacy and reliability of these devices in managing chronic heart rhythm disorders. Dual-chamber pacemakers represent the most advanced implantable category, enabling physiological pacing by coordinating atrial and ventricular contractions, thereby improving hemodynamic efficiency and patient outcomes. Cardiac Resynchronization Therapy (CRT) pacemakers address heart failure patients with ventricular dyssynchrony, delivering synchronized electrical stimulation to both ventricles to restore coordinated contraction patterns. These devices have demonstrated significant improvements in exercise tolerance, quality of life, and survival rates in heart failure populations. External Pacemakers represent a smaller but critical market segment, primarily used in acute care settings for temporary pacing during cardiac emergencies, post-operative management, and bridge therapy before permanent device implantation. Pacing Leads constitute essential components connecting the pacemaker generator to the heart tissue, with continuous innovation improving lead durability, sensing capabilities, and biocompatibility. The leadless pacemaker segment, while currently representing a smaller market share, is experiencing the fastest growth trajectory. Leadless devices eliminate traditional leads and surgical pockets, significantly reducing long-term complications including lead fracture, venous obstruction, pocket infections, and device erosion. Abbott Laboratories' Aveir VR and Medtronic's Micra AV represent advanced leadless platforms with retrievability and atrioventricular synchrony capabilities, expanding eligible patient populations and driving adoption across diverse clinical settings.

Based on Indication

By indication, the Arrhythmia segment is expected to account for the largest share of the market in 2026. Arrhythmias, including bradycardia and atrial fibrillation, represent the most common indications for pacemaker implantation. Bradycardia, characterized by abnormally slow heart rates, frequently occurs in elderly populations and can result from sinoatrial (SA) node dysfunction or atrioventricular (AV) block. Atrial fibrillation, the most prevalent cardiac arrhythmia, affects millions globally and often requires rate-control pacing strategies. The rising prevalence of these conditions, coupled with growing awareness among patients and healthcare providers about pacemaker therapy benefits, drives this segment's growth. Congestive Heart Failure (CHF) represents the second major indication segment, with CRT pacemakers specifically designed to address ventricular dyssynchrony in heart failure populations. The growing prevalence of heart failure, driven by aging populations, hypertension, diabetes, and coronary artery disease, creates substantial market opportunities. CRT pacemakers have demonstrated significant clinical benefits including improved left ventricular ejection fraction, reduced hospitalizations, and enhanced survival rates, supporting their adoption in heart failure management protocols.

Based on End User

By end user, Hospitals & Clinics are expected to be the dominant segment throughout the forecast period. These facilities possess advanced electrophysiology laboratories equipped with sophisticated imaging and monitoring capabilities necessary for complex pacemaker implantation procedures. Hospitals employ specialized electrophysiology teams with extensive training in device selection, implantation techniques, and post-operative management. Ambulatory Care Centers represent a growing segment, particularly for routine device implantations and follow-up procedures. These facilities offer cost-effective alternatives to hospital-based procedures, improving patient access and reducing healthcare expenditures. The shift toward ambulatory settings is accelerating due to improved procedural efficiency, reduced infection risks, and enhanced patient convenience. Both settings increasingly integrate remote monitoring platforms, enabling continuous device surveillance and proactive clinical interventions.

Geographic Analysis

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. North America is projected to account for the largest share of the global cardiac pacemaker devices market throughout the forecast period. The region's leadership is driven by the high prevalence of cardiovascular diseases, including arrhythmias and heart failure, which continue to increase with the aging population. North America benefits from a well-established healthcare infrastructure, advanced electrophysiology centers, and strong clinical expertise in cardiac device implantation procedures. Favorable reimbursement frameworks and widespread insurance coverage support patient access to implantable cardiac devices, encouraging adoption of technologically advanced pacemaker systems. Early uptake of innovations including MRI-compatible pacemakers, leadless pacing technologies, and remote monitoring platforms strengthens regional demand. The strong presence of leading manufacturers including Medtronic plc, Abbott Laboratories, and Boston Scientific Corporation supports continuous product innovation, clinical research, and physician training.

Asia-Pacific is expected to register the fastest growth in the global cardiac pacemaker devices market during the forecast period. This growth is mainly attributed to the rising burden of cardiovascular diseases, a large and rapidly aging population, and improving diagnosis and treatment rates. Increasing healthcare expenditure, expansion of hospital infrastructure, and government initiatives to enhance access to advanced cardiac care contribute to market growth. Greater awareness of minimally invasive cardiac procedures and increasing adoption of implantable cardiac devices accelerate demand across the region. Major economies such as China and India serve as key growth engines due to their large patient pools, expanding private healthcare sectors, and rising investments in medical technology. The growing presence of regional manufacturers and improving affordability of cardiac devices further support market penetration.

Europe demonstrates steady market growth supported by advanced healthcare systems, strong clinical research infrastructure, and high adoption rates of innovative cardiac technologies. Latin America and the Middle East & Africa represent emerging market opportunities with growing healthcare infrastructure investments and increasing recognition of cardiac device importance for cardiovascular disease management.

Key Players

The global cardiac pacemaker devices market is characterized by the presence of several large, well-established companies and numerous smaller, specialized players. Key companies profiled in this market include Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, and other leading cardiac device manufacturers. These companies offer comprehensive pacemaker portfolios spanning implantable systems, external pacemakers, pacing leads, and remote monitoring platforms while actively engaging in research and development to develop more advanced and integrated solutions. Competition in this market is driven by technological innovation, clinical evidence generation, regulatory approvals, and the ability to provide comprehensive solutions addressing complex patient needs. Strategic partnerships between device manufacturers, healthcare providers, and technology companies are accelerating market innovation and enabling rapid technology deployment.

Key Questions Answered in the Report-

• What is the current revenue generated by the global cardiac pacemaker devices market?
• At what rate is the global cardiac pacemaker devices market demand projected to grow for the next 7-10 years?
• What are the historical market sizes and growth rates of the global cardiac pacemaker devices market?
• What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants?
• Which segments in terms of product, indication, and end user are expected to create major traction for vendors in this market?
• What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities?
• Who are the major players in the global cardiac pacemaker devices market? What are their specific product offerings and strategic positioning?
• What are the recent strategic developments in the global cardiac pacemaker devices market? What are the impacts of these developments on market dynamics?

Scope of the Report:

Cardiac Pacemaker Devices Market Assessment -- by Product

• Implantable Pacemakers (Dual Chamber Pacemakers, CRT Pacemakers, Single Chamber Pacemakers)
• Leadless Pacemakers
• External Pacemakers
• Pacing Leads

Cardiac Pacemaker Devices Market Assessment -- by Indication

• Arrhythmia (Bradycardia, Atrial Fibrillation, Atrioventricular Block)
• Congestive Heart Failure (CHF)

Cardiac Pacemaker Devices Market Assessment -- by End User

• Hospitals & Clinics
• Ambulatory Care Centers

Cardiac Pacemaker Devices Market Assessment -- by Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• UAE
• South Africa
• Rest of Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1 Market Definition
• 1.2 Scope of the Study
• 1.3 Market Ecosystem
• 1.4 Currency & Limitations

2. Research Methodology

• 2.1 Research Approach
• 2.2 Data Collection & Validation
• 2.3 Market Assessment
• 2.4 Assumptions for the Study

3. Executive Summary

4. Market Insights

• 4.1 Introduction
• 4.2 Market Dynamics
  • 4.2.1 Drivers
    • 4.2.1.1 Rising prevalence of cardiovascular diseases and arrhythmias
    • 4.2.1.2 Growing geriatric population prone to cardiac disorders
    • 4.2.1.3 Technological advancements in miniaturized and MRI-compatible pacemakers
    • 4.2.1.4 Increasing adoption of minimally invasive procedures
  • 4.2.2 Restraints
    • 4.2.2.1 High cost of implantable cardiac devices
    • 4.2.2.2 Product recalls and device-related complications
    • 4.2.2.3 Stringent regulatory approval processes
  • 4.2.3 Opportunities
    • 4.2.3.1 Expanding healthcare access in emerging markets
    • 4.2.3.2 Development of leadless and wireless pacemaker technologies
    • 4.2.3.3 Growing demand for remote patient monitoring integration
  • 4.2.4 Trends
    • 4.2.4.1 Shift toward leadless pacemakers
    • 4.2.4.2 Integration of AI and advanced diagnostics
    • 4.2.4.3 Growth in home-based cardiac monitoring ecosystems
• 4.3 Porter's Five Forces Analysis

5. Cardiac Pacemaker Devices Market, by Product

• 5.1 Introduction
• 5.2 Implantable Pacemakers
  • 5.2.1 Dual-Chamber Pacemakers
  • 5.2.2 Single-Chamber Pacemakers
  • 5.2.3 Cardiac Resynchronization Therapy (CRT) Pacemakers
• 5.3 External Pacemakers
• 5.4 Pacing Leads
  • 5.4.1 Active Fixation Leads
  • 5.4.2 Passive Fixation Leads

6. Cardiac Pacemaker Devices Market, by Indication

• 6.1 Introduction
• 6.2 Arrhythmia
• 6.3 Congestive Heart Failure (CHF)
• 6.4 Other Indications

7. Cardiac Pacemaker Devices Market, by End User

• 7.1 Introduction
• 7.2 Hospitals & Clinics
• 7.3 Ambulatory Care Centers
• 7.4 Other End Users

8. Cardiac Pacemaker Devices Market, by Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 France
  • 8.3.3 U.K.
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia-Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 South Korea
  • 8.4.5 Australia
  • 8.4.6 Rest of Asia-Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 South Africa
  • 8.6.4 Rest of Middle East & Africa

9. Competitive Landscape

• 9.1 Introduction
• 9.2 Market Share Analysis
• 9.3 Competitive Growth Strategies
• 9.4 Product Benchmarking
• 9.5 Vendor Positioning Matrix

10. Company Profiles

• 10.1 Medtronic plc
• 10.2 Abbott Laboratories
• 10.3 Boston Scientific Corporation
• 10.4 BIOTRONIK SE & Co. KG
• 10.5 LivaNova PLC
• 10.6 MicroPort Scientific Corporation
• 10.7 Lepu Medical Technology
• 10.8 Shree Pacetronix Ltd.
• 10.9 Oscor Inc.
• 10.10 Cook Medical
• 10.11 Others

11. Appendix

• 11.1 Questionnaire
• 11.2 Available Customization